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Abstract
The human hyaluronan receptor for endocytosis (hHARE) medi-
ates the endocytic clearance of hyaluronan (HA) and chondroitin 
sulfate from lymph fluid and blood. Two hHARE isoforms (190 
and 315 kDa) are present in sinusoidal endothelial cells of liver, 
spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A., 
Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339–349). 
Here we report the specificity and function of the 190-kDa HARE, 
expressed without the larger isoform, in Flp-In 293 cell lines 
(190hHARE cells). Like the native protein, recombinant hHARE 
contains ~25 kDa of N-linked oligosaccharides, binds HA in a li-
gand blot assay, cross-reacts with three anti-rat HARE monoclo-
nal antibodies, and is inactivated by reduction. The 190hHARE 
cell lines mediated rapid, continuous 125I-HA endocytosis and 
degradation for >1 day. About 30–50% of the total cellular recep-
tors were on the cell surface, and their recycling time for reutiliza-
tion was ~8.5 min. The average Kd for the binding of HA to the 
190-kDa hHARE at 4 °C was 7 nm with 118,000 total HA binding 
sites per cell. Competition studies at 37 °C indicated that the 190-
kDa hHARE binds HA and chondroitin better than dermatan sul-
fate and chondroitin sulfates A, C, D, and E, but it does not bind to 
heparin, heparan sulfate, or keratan sulfate. Although competition 
was observed at 37 °C, none of the glycosaminoglycans tested, ex-
cept HA, competed for 125I-HA binding by 190hHARE cells at 4 
°C. Anti-HARE monoclonal antibodies #30 and #154, which do 
not inhibit 125I-HA uptake mediated by the 175-kDa rat HARE, 
partially blocked HA endocytosis by the 190-kDa hHARE. We 
conclude that the 190-kDa hHARE can function independently of 
other hHARE isoforms to mediate the endocytosis of multiple gly-
cosaminoglycans. Furthermore, the rat and human small HARE 
isoforms have different glycosaminoglycan specificities and sensi-
tivities to inhibition by cross-reacting antibodies. 
Abbreviations: HA, hyaluronic acid, hyaluronate, or hyaluronan; CS, 
chondroitin sulfate; CS-A, chondroitin 4-sulfate; CS-C, chondroitin 
6-sulfate; CS-D, chondroitin 2,6-sulfate; CS-E, chondroitin 4,6-sulfate; 
DS, dermatan sulfate; ECM, extracellular matrix; GAG, glycosamino-
glycan; HARE, HA receptor for endocytosis; hHARE, human HARE; 
HBSS, Hanks’ balanced salt solution; Hep, heparin; HS, heparan sul-
fate; KS, keratan sulfate; LECs, liver sinusoidal endothelial cells; mAb, 
monoclonal antibody; PBS, phosphate-buffered saline; rHARE, rat 
HARE; SK-HARE, stable SK-Hep-1 cell lines expressing recombinant 
rat HARE; Tris, trishydroxymethylamino methane; TBS, Tris-buffered 
saline; TBST, Tris-buffered saline containing 0.05% Tween 20; BSA, 
bovine serum albumin; DMEM, Dulbecco’s modified Eagle’s medium; 
Chon, chondroitin
Multiple extracellular binding proteins and cell surface re-
ceptors for HA facilitate many biological activities that are im-
portant during complex cellular processes, including devel-
opment, wound healing, and invasion and metastasis of some 
cancers (1–5). Due to the rapid turnover of HA in many tissues 
(6), very high HA levels could occur locally, in lymph fluid, or 
in plasma. Therefore, efficient mechanisms for HA uptake and 
degradation are present in mammals to regulate the amount of 
HA present in a variety of physiological conditions (reviewed 
in References 2 and 7). 
The endocytic clearance receptor for HA, which is desig-
nated HARE (HA receptor for endocytosis), is abundant in the 
sinusoidal endothelial cells of liver, spleen, and lymph nodes 
(8–10). The biological activity of this clearance receptor was 
discovered in rodents in 1981 (11–13), and the protein was fi-
nally purified by Zhou et al. in 1999 (14). Earlier studies using 
isolated rat LECs indicated that HARE mediates the binding 
and endocytosis of HA via the coated-pit pathway and that 
this receptor also recognizes and internalizes chondroitin sul-
fates (15–17). Unlike the rat HARE proteins, which have been 
studied extensively in isolated rat LECs, there have been no 
cellular studies of the human HARE proteins. Human LECs 
are not available commercially, and to date, no cell lines have 
been identified that express either the 190- or 315-kDa hHARE 
isoforms. Consequently, very little is known about the GAG 
specificity or function of human HARE. 
In both rat (14) and human (10), two isoforms of HARE are 
present with molecular masses of 175 or 300 kDa and 190 or 
315 kDa, respectively. The human ~315-kDa HARE is a com-
plex composed of two disulfide-bonded subunits of about 
250 and 220 kDa, in a ratio of ~2:1 (10). In contrast, the small 
hHARE isoform contains a single subunit. All subunits in 
both hHARE isoforms, although they are different sizes, ap-
pear to be derived by proteolysis from the same precursor 
protein (9), which is Stabilin 2 (18). Full-length Stabilin 2 is a 
very large putative protein (2551 amino acids), whose synthe-
sis and processing have not yet been fully elucidated. For ex-
ample, it is not known if the largest subunit in the 315-kDa 
hHARE corresponds to full-length Stabilin 2 or to a truncated 
form of the protein. The small rat and human HARE proteins 
are not encoded directly by mRNA. We recently demonstrated 
(9) that the native small rHARE isoform contains the C-termi-
nal 1431 residues of the predicted full-length protein and that 
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this smaller HARE, when expressed in SK-Hep-1 cells in the 
absence of the large isoform, colocalizes with clathrin as ex-
pected for a coated-pit-coupled endocytic HA receptor (19). 
The two rat HARE species, therefore, appear to be functionally 
independent isoreceptors for HA. 
In the present study, we have created an artificial spleen 
cDNA for the 190-kDa hHARE to assess its functionality and 
GAG specificity in stable cell lines. In addition to demonstrat-
ing that this smaller hHARE isoform can function as an endo-
cytic, recycling receptor in the absence of the larger hHARE, 
we found that the human protein has slightly different spec-
ificity for various GAGs than the highly related rat 175-kDa 
HARE isoform. Unexpectedly, several anti-HARE mAbs 
showed very different reactivity with the rat and human re-
combinant HARE proteins and were able to block partially the 
internalization of HA by cells expressing the 190-kDa hHARE. 
Experimental Procedures
Materials and Buffers—Na125I was from Amersham Biosciences, and 
125I-HA was prepared as described previously (20) using HA oligosac-
charides (MW = 133,000 based on gel permeation chromatography cou-
pled to multiangle laser light scattering analysis), modified only at their 
reducing ends to contain covalently attached hexylamine. Male Sprague-
Dawley rats (200 g) were from Charles River Labs. BSA Fraction V and 
fetal bovine serum were from Intergen Co. Collagenase was from Roche 
Applied Science. The preparation and characterization of mouse mAbs 
raised against the rat 175-kDa HARE were described previously (8). Tris, 
SDS, ammonium persulfate, N,N′-methylenebisacrylamide, and SDS-
PAGE standards were from Bio-Rad. Digitonin, from ACROS Organ-
ics, was prepared as a 25% (w/v) stock solution in Me2SO and then di-
luted into medium as required. Unless noted otherwise, other chemicals 
and reagents were from Sigma Chemical Co. All GAGs (with the excep-
tion of heparin, which came from Sigma) were obtained from Seikagaku 
Corp. The weight-average molecular masses (determined by gel perme-
ation chromatography coupled to multiangle laser light scattering analy-
sis) for all but two of the GAGs were 14.2–38.8 kDa. The two exceptions 
were Chon (7.4 kDa) and CS-E (187.7 kDa). Nitrocellulose membranes 
were from Schleicher & Schuell. HBSS and PBS were prepared according 
to the Invitrogen catalog formulations. Z-buffer contains 60 mm diba-
sic sodium phosphate and 40 mm monobasic sodium phosphate, pH 7.0, 
10 mm KCl, 1.0 mm MgSO4, and 50 mm 2-mercaptoethanol. TBS con-
tains 20 mm Tris-HCl, pH 7.0, and 150 mm NaCl. TBST is TBS containing 
0.05% (v/v) Tween 20. 
Construction of hHARE Expression Vector—The 190-kDa hHARE cod-
ing region was amplified from pooled lymph node cDNAs (Marathon sys-
tem; Clontech) using Advantage 2 polymerase (Clontech), and gene-spe-
cific forward (5′-GGATCCTCCTTACCAAACCTGCTCATGCGG-3′) and 
reverse (5′-GGATCCCAGTGTCCTCAAGGGGTCATTG-3′) primers. The 
PCR product representing the artificial cDNA was then purified by aga-
rose gel electrophoresis using a 0.8% gel containing 0.002% crystal violet 
for visualization. The band was excised, gene-cleaned, ligated into pCR-
XL-TOPO, and transformed into TOP10 Escherichia coli cells (Invitrogen). 
Clones were selected and screened for the full-length insert by restriction 
digestion and PCR analysis, and a correct clone was used to prepare and 
isolate the expression vector. The hHARE cDNA was then cut out of the 
pCR-XL-TOPO plasmid and inserted into the BamHI site of pSecTag/
FRT/V5-His-TOPO (Invitrogen). This vector provides a κ light chain se-
cretion signal fused at the N terminus of the hHARE reading frame and 
two epitope tags (V5 and His-6) fused at the C terminus of the gene prod-
uct. After transformation into TOP10 E. coli cells, several clones were se-
lected and size and orientation of the cDNA insert were verified. The com-
plete sequences of promoter, fusion, and cDNA regions of the final clones 
were determined and confirmed to be correct. 
Selection and Characterization of Stable Transfectants Expressing the 190-
kDa hHARE—Flp-In 293 cells (3 × 106; from Invitrogen) were plated in 100-
mm tissue culture dishes the day prior to transfection. Cells in 10 ml of 
antibiotic-free medium were transfected by addition of 750 μl of serum-
free DMEM containing 9 μg of pOG44 (which encodes the Flp-In recom-
binase), 1 μg of pSecTag-190hHARE, and 20 μl of LipofectAMINE 2000 
(Invitrogen). Two days post-transfection the medium was replaced with 
DMEM containing 100 μg/ml hygromycin B (Invitrogen). Due to the 
build-up of dead cells, the medium was changed every 2–3 days. Visi-
ble colonies were observed at days 10–14 and then isolated using cloning 
rings or collected directly with a plastic pipette tip. Isolated colonies were 
grown to confluence in 24-well dishes in 1.0 ml of DMEM with 100 μg/ml 
hygromycin B. After a monolayer of cells had developed from each clone, 
the cells were scraped and suspended in 1.0 ml of fresh medium. One por-
tion (100 μl) of cells was re-seeded and allowed to grow for subsequent 
procedures. Another 100 μl of cells was resuspended in DMEM plus 100 
μg/ml Zeocin and allowed to grow for 1 week to test for Zeocin sensitiv-
ity. A third portion (400 μl) of cells was pelleted and resuspended in 4× 
Laemmli sample buffer (21) to test for HARE protein expression by SDS-
PAGE and Western analysis. The Western blot was probed with anti-V5 
antibody (Bethyl Laboratories; 1:5000 dilution) in TBST. 
The remaining 400 μl of cell suspension was pelleted and assayed 
for β-galactosidase activity. Both the Zeocin and β-galactosidase tests in-
dicate whether pSecTag-190-kDa hHARE was inserted correctly and 
uniquely into the Flp-In recombination site by the Flp-In recombinase en-
coded by pOG44. The recombinase is lost during subsequent cell divi-
sions, because the encoding plasmid lacks an antibiotic selection gene. For 
the β-galactosidase assay, a clonal cell pellet was resuspended in 250 μl 
of 0.5% Triton X-100 in PBS, and 10 μl of cell lysate per well (in a 96-well 
plate) was combined with 20 μl of distilled deionized H2O, 70 μl of Z-buf-
fer, and 20 μl of 4 mg/ml o-nitrophenyl-β-d-galactoside in Z-buffer. Af-
ter 15 min at 37 °C, the enzyme reaction was terminated by the addition of 
0.1 ml 1 m sodium bicarbonate, and absorbance values were determined 
at 420 nm. Human embryonic kidney Flp-In 293 cells and 293 cells were 
included in each assay set as positive and negative controls, respectively. 
Stable clones with a single plasmid integrated into the correct, unique 
chromosomal site were those that demonstrated and maintained no de-
tectable β-galactosidase expression, poor or no growth in DMEM contain-
ing 100 μg/ml Zeocin, normal cell morphology, and good HARE protein 
expression. Suitable clones were maintained in DMEM containing 100 μg/
ml hygromycin B and 8% fetal bovine serum. 
Western and Ligand Blot Assays—Western blotting was performed as 
described by Burnette (22) with minor modifications. Cell lysates were 
mixed with equal volumes of 2× SDS sample buffer (21), without reduc-
ing agent, to give final concentrations of 16 mm Tris-HCl, pH 6.8, 2% 
(w/v) SDS, 5% glycerol (v/v), and 0.01% bromphenol blue. After SDS-
PAGE, the contents of the gel were electrotransferred to a nitrocellu-
lose membrane overnight at 10 V at 4 °C using 25 mm Tris, pH 8.3, 192 
mm glycine, 20% methanol, and 0.01% SDS in a Genie blotter apparatus 
(Idea Scientific). For the ligand blot assay, the nitrocellulose membrane 
was treated first with TBS containing 0.1% Tween 20 at 4 °C for 2 h, or 
TBST overnight, and then incubated with 1–2 μg/ml 125I-HA in 150 mm 
NaCl, 10 mm HEPES, pH 7.4, and 5 mm EDTA without, or with, a 100- 
to 150-fold excess of nonlabeled HA (as competitor) to assess total and 
nonspecific binding, respectively (23). The nitrocellulose membrane was 
washed with TBST five times for 5 min each and dried at room tempera-
ture. Bound 125I-HA was detected by autoradiography using Kodak Bio-
Max MS or MR film exposed at –85 °C for 6–48 h. Nonspecific binding in 
this assay is typically <5%. 
For Western analysis, the nitrocellulose membranes were blocked 
with 1% BSA in TBS at 4 °C overnight either after the ligand blot assay 
(the membranes were rewet with TBST first) or directly after SDS-PAGE 
and electrotransfer. The membrane was then incubated with anti-rat 
HARE mAbs (e.g. 1 μg/ml IgG) at 22 °C for 1 h, washed three times for 
5 min each with TBST, and incubated with goat anti-mouse Ig-alkaline 
phosphatase conjugate (1:1500 dilution) for 1 h at room temperature. The 
nitrocellulose was washed with TBST five times for 5 min each and incu-
bated with p-nitro blue tetrazolium and sodium 5-bromo-4-chloro-3-in-
dolyl phosphate p-toluidine for color development (Bio-Rad), which was 
stopped by washing the membrane with distilled water. 
125I-HA Binding or Endocytosis Assays—Stably transfected 190-kDa 
hHARE cell lines were grown to confluence in DMEM containing 8% fe-
tal calf serum and 100 μg/ml hygromycin B in tissue culture multiwell 
dishes (usually 24-well plates). The cells were washed with HBSS and in-
cubated at 37 °C in fresh medium without serum for 30–60 min, the plates 
were then placed on ice, and the cells washed once or twice with HBSS 
prior to the experiment. Medium containing 1–2 μg/ml 125I-HA with or 
without the noted concentration of IgG or other GAG (as competitor) was 
added to each well, and the cells were incubated either on ice for 60 min 
to assess cell surface binding or at 37 °C to allow internalization of ligand. 
To assess HA binding by the total cell receptor population, 0.055% (w/v) 
digitonin was added to the medium to permeabilize the cells (24, 25). At 
the noted times, the medium was removed by aspiration, the cells were 
washed three times with HBSS and lysed in 0.3 n NaOH, and radioactiv-
ity and protein content were determined. Values were normalized for cell 
protein content per well and are presented as cpm/μg of protein. In some 
cases, HA data are expressed as cpm or femtomoles per million cells. For 
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Flp-In 293 cells, the mean protein content was determined to be 398 ± 85 
μg of protein/106 cells (n = 6). 
125I-HA Degradation Assay—Degradation of 125I-HA was measured by 
a cetylpyridinium chloride precipitation assay as described by McGary et 
al. (26). 50-μl samples of medium were mixed with 250 μl of 1 mg/ml HA 
in 1.5-ml microcentrifuge tubes. Alternatively, 100-μl samples of cell lysate 
(in 0.3 n NaOH) were mixed with 47 μl of 0.6 n HCl, 28 μl of distilled wa-
ter, and 125 μl of 2.0 mg/ml HA. After mixing at room temperature, 300 
μl of 6% (w/v) cetylpyridinium chloride in distilled water was added, and 
the tubes were mixed by vortexing. After 10 min, the samples were cen-
trifuged at 22 °C for 5 min at 9000 rpm in an Eppendorf model 5417 mi-
crocentrifuge, using a swinging bucket rotor. A sample (300 μl) of the su-
pernatant was taken for determination of radioactivity, and the remainder 
was removed by aspiration. The tip of the tube containing the precipitated 
pellet was cut off then put in a gamma counter tube, and radioactivity was 
determined. Degradation was measured as the time-dependent increase 
of nonprecipitable radioactivity. At least 80% of the total radioactivity was 
precipitable at the beginning of each experiment. 
General—Protein content was determined by the method of Brad-
ford (27) using BSA as a standard. SDS-PAGE was performed according 
to the method of Laemmli (21). 125I radioactivity was measured using a 
Packard Auto-Gamma Counting system. Digital images were captured 
using an Alpha Innotech Fluorochem 8000. Images were taken into Corel 
Photo Paint (version 9.0) as JPG files, cropped and processed identically, 
and then transferred to Corel Draw (version 9.0) for annotation. N-ter-
minal amino acid sequence analysis was performed by the University of 
Oklahoma Health Sciences Center, Molecular Biology Resource Facility. 
Results
Expression of Recombinant Human 190-kDa HARE—We re-
cently purified two hHARE proteins, of 190 and 315 kDa, from 
spleen extracts and then molecularly cloned a partial cDNA 
from pooled human lymph node and spleen that encoded part 
or all of the subunits in these two isoforms (10). The 190-kDa 
hHARE protein is not expressed from a unique mRNA, but 
rather is encoded by a 4383-bp region (1461 amino acids) at the 
3′ end of the full-length Stab 2 coding region. To express the 
190-kDa protein, we created an artificial cDNA for a recom-
binant 190-kDa hHARE in the pSecTag/FRT/V5/His-TOPO 
expression vector. For proper membrane orientation and traf-
ficking to the cell surface, the pSecTag vector provides an im-
munoglobulin κ-chain secretion signal sequence fused at the N 
terminus of the protein. Transiently transfected Flp-In 293 cells 
expressed sufficiently high levels of the recombinant 190-kDa 
hHARE to mediate the specific binding and internalization of 
125I-HA (Figure 1). Compared with vector alone, cells trans-
fected with hHARE cDNA internalized ~4 times the amount 
of HA, and this uptake was completely blocked by unlabeled 
HA. Specific HA uptake, therefore, was ~80% of the total. 
The potential advantage of using Flp-In 293 cells as the pa-
rental cell line for generation of stable cell lines expressing 
hHARE is that all clones should be virtually identical if the plas-
mid inserts at only the single unique chromosome site contain-
ing the engineered integration site. Correct integration at this 
site interrupts a β-galactosidase gene and a Zeocin resistance 
gene in the engineered site. Clones containing a single plasmid 
insertion at the correct engineered site are, therefore, hygromy-
cin B-resistant, negative for β-galactosidase activity, and Zeo-
cin-sensitive. If plasmid insertion occurs at other chromosome 
sites, rather than the correct engineered site, then clones will ex-
press β-galactosidase and be Zeocin-resistant. Out of 41 stably 
transfected clones that we selected and characterized, three (#9, 
#14, and #40) had no detectable β-galactosidase activity, were 
Zeocin-sensitive, and were judged to contain a plasmid inser-
tion at the unique engineered site. 
A protein of the correct size for the 190-kDa hHARE was 
expressed in the three selected stable Flp-In 293 cell lines, and 
this protein bound 125I-HA with >98% specificity in a ligand 
blot assay following SDS-PAGE and electrotransfer (Figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2A). The 190-kDa hHARE protein expressed in Flp-In 293 cells 
had the characteristics previously found for native hHARE 
purified from spleen (10), and expression of the 190-kDa 
hHARE did not alter the morphology of Flp-In 293 cells. The 
recombinant nonreduced protein was recognized in Western 
blots by the three anti-rHARE mAbs that cross-reacted with 
native hHARE (mAbs 30, 154, and 159) but not mAbs 28, 174, 
235, and 467 (Figure 2B, NR). Similarly, the reduced 190-kDa 
hHARE protein reacted with only mAbs 159 and 174 (Figure 
2B, R). Based on its HA-binding activity in these in vivo and 
in vitro assays, the recombinant hHARE protein appeared to 
be folded properly. Consistent with this interpretation, three 
other characteristics of the recombinant hHARE were identi-
cal to those of the native protein (10). Reduction of disulfide 
bonds resulted in slower migration of the 190-kDa hHARE in 
SDS-PAGE compared with the nonreduced protein (Figure 2C, 
lanes 1 and 3, WB). Reduction of disulfide bonds also caused 
loss of HA-binding activity (Figure 2C, lanes 1 and 3, AR). Af-
ter treatment with endoglycosidase-F to release N-linked oli-
gosaccharides, the recombinant protein migrated at a position 
corresponding to a loss of ~25 kDa (Figure 2C, lanes 3 and 4, 
WB). The de-N-glycosylated hHARE protein was still able to 
bind HA in this ligand blot format (Figure 2C, lane 4, AR). In 
addition, anti-V5 antibody recognition of the C-terminal epit-
ope provided by the vector was suitable for immunoprecipita-
tion (not shown). 
HA Binding and Internalization by Cells Expressing the 190-
kDa hHARE—The specific binding of 125I-HA at 4 °C by sta-
ble cell lines was typical for a membrane-bound receptor; 
binding kinetics was hyperbolic and saturated after about 90 
min (Figure 3). Essentially no specific binding of 125I-HA oc-
curred in the control cells transfected with empty vector, con-
sistent with the absence of any significant HA receptor activity 
in 293 cells (Table I). Also, as found for other endocytic, recy-
cling receptors (e.g. the asialoglycoprotein and mannose re-
ceptors), about 30–50% of the total cellular hHARE population 
was on the cell surface, and the remainder was intracellular. 
The native rHARE in isolated LECs is an active endocytic re-
ceptor that recycles so that HA can be continually internal-
ized and delivered to lysosomes for degradation over a period 
of many hours to days (7, 17, 26). To assess the ability of the 
recombinant 190-kDa hHARE to recycle, cells were allowed 
Figure 1. Transiently transfected 293 Flp-In cells express the HA-bind-
ing recombinant 190-kDa hHARE protein. 293 Flp-In cells (5 × 104 per 
well) grown in 24-well plates were transfected with pSecTag-190-kDa 
hHARE/ExGEN500 or pSecTag/ExGEN500 complexes and allowed 
to recover for 2 days. The transfected cells were allowed to bind and 
endocytose 1 μg/ml 125I-HA with (H+C) or without (H) 100 μg/ml un-
labeled HA in serum-free medium for 3 h at 37 °C. Cells were washed 
with ice-cold HBSS and solubilized in 0.3 m NaOH, and radioactivity 
and protein were determined (n = 3; ±S.E.). 
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to internalize 125I-HA for 4 h, and the amount of specific HA 
uptake was calculated as the number of cell surface receptor 
equivalents. This estimates the approximate number of times 
that a cohort of cell surface HARE proteins would have to be 
used to achieve the observed level of HA uptake. For 190-kDa 
hHARE Flp-In 293 clones 9 and 14, these recycling ratios were 
25 and 32, respectively (Table I). Based on these values of 25–
32 surface equivalents of HA internalized in 240 min, the esti-
mated individual receptor recycling time is 7.5–9.6 min, which 
is identical to the recycling times reported for all the known 
coated-pit-mediated clearance receptors that recycle (7, 19). 
Consistent with the conclusion that the recombinant 190-
kDa hHARE is a recycling receptor able to mediate the contin-
uous endocytosis of ligand, the Flp-In 293 cell lines expressing 
hHARE, but not the vector-alone control, were able to inter-
nalize 125I-HA for ≥20 h before cellular accumulation appeared 
to level off (Figure 4). The apparent saturation of HA uptake 
is a steady-state situation, however, because cells are still en-
docytosing 125I-HA while they are releasing radioactive degra-
dation products into the medium at the same rate. The ability 
of cells to process (i.e. internalize, degrade, and secrete degra-
dation products) large amounts of ligand over many hours or 
days is characteristic of recycling receptors that operate via the 
coatedpit pathway (7, 19, 28). 
Scatchard Analysis of 125I-HA Binding by Recombinant 190-kDa 
hHARE—Because no ligand binding information exists for the 
individual hHARE species, equilibrium binding studies were 
performed using 190hHARE Flp-In 293 clones #9 and #14 to 
determine total receptor content and the affinity of the HA-
hHARE interaction (Figure 5). Based on the concentration of un-
labeled HA required for half-maximal competition of 125I-HA 
binding, the apparent Km for HA binding is 1–2 μg/ml or ~10 
nm (Figure 5A). When these data were normalized for the spe-
cific radioactivity of the bound 125I-HA at each point, the result-
ing binding isotherm was hyperbolic, which is typical of many 
receptor-ligand interactions, and binding approached satura-
tion at >80 μm HA (Figure 5B). When analyzed according to 
the method of Scatchard (29), the data in replicate experiments 
were best fit by a single straight line (cc ≥ 0.9), indicating that a 
single class of noninteracting HA binding sites was present in 
digitonin-permeabilized cells (Figure 5C). Based on two inde-
pendent experiments with both clones #9 and #14 (n = 8) the 
mean (±S.D.) Bmax and Kd values were 196 ± 45 fmol of total HA 
binding sites/106 cells and 7.2 ± 1.2 nm, respectively. The Bmax 
value corresponds to ~118,000 total HA binding sites per cell. 
Figure 3. Kinetics of 125I-HA binding by stable cell lines expressing the 
190-kDa hHARE. Confluent cell cultures of hHARE expression clones 
#9 (•) and #14 (▪) were incubated at 37 °C in medium without serum 
for 60 min. The plates were placed on ice, and the wells were washed 
once with HBSS. The cells were permeabilized at 4 °C with 0.55% digi-
tonin in PBS to allow access to both surface and internal receptors (24, 
25). The cells were washed and then incubated in medium containing 
1.5 μg/ml 125I-HA with or without 150 μg/ml unlabeled HA. At the 
noted times, the cells were washed three times with HBSS and solubi-
lized in 0.3 n NaOH, and protein and radioactivity were determined 
as under “Experimental Procedures.” Data shown represent specific 
binding; each point is the average of duplicate wells without excess 
HA (total binding) minus the average of duplicate wells with excess 
HA (nonspecific binding). 
Figure 2. The 190-kDa hHARE is expressed abundantly and is biolog-
ically functional in stably transfected 293 Flp-In cells. A, whole cell ly-
sates from three clones expressing the 190-kDa hHARE (9, 14, and 
40) and one clone transfected with empty vector (EV) were subjected 
to nonreducing SDS-PAGE using a 5% gel, followed by electrotrans-
fer to nitrocellulose. Bottom panels: after blocking in 0.1% Tween-20 in 
TBS for 3 h at room temperature, ligand blotting and autoradiogra-
phy (AR) were performed, using 1.0 μg/ml 125I-HA with (left) or with-
out (right) 100 μg/ml unlabeled HA, as described under “Experimental 
Procedures.” Top panels: the same nitrocellulose strips were then rewet-
ted and blocked with 1% BSA in TBS, and Western blot (WB) analysis 
was performed using a mixture of mAb-30, mAb-154, and mAb-159. B, 
whole cell lysates from clone #9 were subjected to nonreducing (NR) or 
reducing (R) SDS-PAGE using a 5% gel and electrotransfer to nitrocellu-
lose. After blocking for 2 h in 1% BSA in TBS, the nitrocellulose was cut 
into strips and subjected to Western blot analysis with 1 μg/ml of the 
indicated seven mAbs previously raised against the rat 175-kDa HARE. 
C, cells expressing the 190-kDa hHARE protein were lysed in Laemmli 
buffer and either treated with endoglycosidase F and/or reduced with 
10 mm dithiothreitol. Proteins were separated on a 5% SDS-PAGE. Bot-
tom panel: the transfer was incubated with 1 μg/ml 125I-HA with (left) or 
without (right) 100 μg/ml unlabeled HA for 2 h at 4 °C and washed, and 
autoradiography was performed. Top panel: the nitrocellulose was then 
rewetted in 1% BSA in TBS, and Western blot analysis was performed to 
identify hHARE using anti-V5 antibody. 
en d o c y t i c Fu n c t i o n, gag sp e c i F i c i t y,  a n d an t i b o d y in H i b i t i o n o F t H e 190-kda HHare   36205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAG Specificity of the Recombinant 190-kDa hHARE—The 
GAG specificities of the two hHARE isoforms have not been 
determined. Using the stable 190hHARE Flp-In 293 cell lines, 
we examined the ability of individual purified GAG chains to 
block the endocytosis of 125I-HA. Even at 100 μg/ml, KS, HS, 
and heparin did not compete for HA binding and uptake at 
37 °C, and DS showed a modest ~15% inhibition (Figure 6). 
This latter slight inhibition by DS appears to be significant, 
because it was observed in other experiments as noted be-
low. CS-A was the most effective inhibitor, although its block-
ing ability was not comparable to that of HA, e.g. at 30 μg/
ml ~45% inhibition was observed with CS-A versus ~70% in-
hibition with HA (Figure 6A). Four other GAGs, including 
chondroitin (Figure 6A) and CS-C, CS-D, and CS-E (Figure 6B) 
gave very similar titration profiles, with ~50% inhibition at 100 
μg/ml. For comparison, 100 μg/ml HA blocked 125I-HA up-
take by ~87%. In contrast to these results at 37 °C, none of the 
GAGs tested, except for HA, competed for 125I-HA binding to 
190hHARE Flp-In 293 cells at 4 °C (Figure 7). 125I-HA binding 
in the presence of the other nine GAGs ranged within 10% of 
the no-addition control value. The binding of GAGs other than 
HA to the 190-kDa hHARE protein, thus, appears to be very 
temperature-dependent. 
The ability of the 190-kDa hHARE to interact with GAGs 
was also assessed in a ligand blot format in which whole cell 
extracts were probed, in a Western blot format, with 125I-HA 
(23). As shown in Figure 1A, the level of hHARE protein ex-
pression in extracts is high enough to obtain an excellent sig-
nal, by autoradiography, in this assay within 6–18 h. The abil-
ity of various GAGs to compete for 125I-HA binding to the 
190-kDa hHARE in the ligand blot assay (Figure 8) closely par-
alleled the pattern seen for competition of endocytosis by cells, 
with the exception of HS. No competition was observed with 
KS or Hep. As with live cells, Chon, DS, and all the CS types 
showed significant competition. In contrast, 100 μg/ml HS 
showed no effect on HA endocytosis in live cells (Figure 6B), 
whereas 50 μg/ml HS inhibited 125I-HA binding by 40% in the 
in vitro ligand blot assay. 
It should be informative to compare the GAG specifici-
ties of the rat and human small HARE isoforms, because the 
amino acid sequences of the extracellular domains of these 
two proteins are 80% identical (10). Such GAG specificity dif-
ferences might reflect significant differences between species 
in the biology of HARE or its role in GAG turnover. Figure 9 
compares the abilities of various GAGs to compete for 125I-HA 
endocytosis by isolated rat LECs expressing both rat HARE 
isoforms, SK-HARE cells expressing the 175-kDa rHARE, and 
Flp-In 293 cells expressing the 190-kDa hHARE. In each of the 
three cell types, little or no competition was observed with KS, 
HS, or Hep. DS competed for HA uptake to the same slight 
extent (~25–30%) in cells expressing either hHARE or rHARE. 
The four CS variants competed for HA uptake by both HARE 
proteins, although the patterns were not identical. The effects 
of CS-A and CS-D were essentially the same, whereas the pref-
erence for CS-C or CS-E was switched between the rat and hu-
man HARE proteins. HA-binding to the hHARE was com-
peted better by CS-E, whereas binding to the rHARE was 
competed better by CS-C. The greatest difference between the 
rat and human HARE was observed for competition by Chon. 
The hHARE appeared to interact more strongly with Chon 
(50% inhibition) than did the rHARE (~10% inhibition). 
Table I.  Surface and intracellular HA binding and receptor recycling during endocytosis. Stable Flp-In 293 cell lines transfected with empty vec-
tor (clone #EV13) or the 190 hHARE cDNA (clones #9 and #14) were grown to confluence, chilled on ice, washed with HBSS, and incubated with 
medium containing 1.5 μg/ml 125I-HA with or without digitonin as described under “Experimental Procedures” to assess total or cell surface 
binding, respectively. A set of parallel cell cultures was incubated at 37 °C for 4 h in medium containing 1.5 μg/ml 125I-HA. Nonspecific binding or 
endocytosis was assessed in the presence of a 100-fold excess of unlabeled HA. Specific values shown are the mean ± S.E. (n = 10 for clones #9 and 
#14) or the average of duplicates for clone #EV13. The receptor recycling ratio is the amount of specific HA endocytosis divided by the specific cell 
surface HA binding. Regardless of cell type, when vertebrate cells are treated with digitonin under the conditions used here, ~50% of the total cel-
lular protein is lost, representing the cytoplasmic contents (24). Therefore, the protein yield for permeable cells is about half that for intact cells. 
       HARE 
Clone #  Surface  Specificity  Total  Specificity  Endocytosis  Specificity  recycling
 cpm/μg  %  cpm/μg  %  cpm/_g  %  Endo/surface
9  12.4 ± 1.9  63.3 ± 10.0  54.2 ± 15.8  75.2 ± 9.5  300.8 ± 34.8  90.1 ± 2.0  24.8 ± 4.2
14  11.9 ± 3.0  50.7 ± 17.3  62.7 ± 21.7  71.3 ± 10.8  365.4 ± 26.8  90.0 ± 2.1  32.3 ± 8.1
EV13  1.3   12.3   1.6   1.3
Figure 4. The recombinant 190-kDa hHARE mediates continuous en-
docytosis and degradation of 125I-HA. A, confluent cell cultures of 
190hHARE-expressing clones #9 (●) and #14 (■) and empty vector 
control clone #13 (▼), in 24-well tissue culture plates, were incubated 
at 37 °C in medium without serum for 30 min. The plates were then 
placed on ice, and the cells were washed once with HBSS. Medium 
containing 1.6 μg/ml 125I-HA with or without 160 μg/ml unlabeled 
HA was added to each well, and the cells were incubated at 37 °Cfor 
up to 4 h to allow internalization. At the noted times, the medium was 
removed, and the cells were washed three times with 1 ml of HBSS 
and lysed in 0.3 n NaOH, and cell protein content and cell-associated 
radioactivity were determined. The data are shown as specific uptake; 
the average radioactivity values of duplicates for total uptake minus 
the average of duplicates for nonspecific uptake. B, clone #14, express-
ing the 190-kDa hHARE, was cultured in 4-well tissue culture plates, 
and processed as in A. In addition, degraded 125I-HA that was cell-as-
sociated and in the medium were also measured at the noted times, as 
described under “Experimental Procedures.” The plots show radioac-
tivity (representing intact and degraded HA) associated with the cells 
(■) and the total degraded 125I-HA (●), i.e. products still inside the cell 
plus those in the medium. 
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Inhibition of 125I-HA Endocytosis by Anti-HARE mAbs—We 
previously developed a panel of eight mouse mAbs against 
the rat 175-kDa HARE protein to facilitate HARE purification 
and characterization (8–10, 14). Seven of these mAbs recog-
nize both nonreduced rHARE proteins and were useful for a 
variety of immunoprocedures. In particular, mAb-174 was ex-
tremely useful, because it completely blocks HA binding to 
the rHARE in LECs (30), in SK-HARE cells (9), or in the ligand 
blot assay (8). A second mAb, #235, partially inhibited HA 
binding to rHARE to a level of ~50%, indicating that HA bind-
ing likely involves multiple protein regions (epitopes). We re-
cently used mAb-174 to demonstrate that HARE is responsible 
for the ability of liver to remove circulating HA, because this 
mAb blocked essentially all 125I-HA uptake in a perfused liver 
system (30). Although mAb-174 and mAb-235 did not recog-
nize hHARE, three of the seven anti-HARE mAbs (#30, #154, 
and #159) cross-reacted with both native hHARE isoforms (10) 
and with the recombinant 190-kDa hHARE (Figure 2B). None-
theless, we tested whether any of the anti-HARE mAbs could 
inhibit the endocytosis of 125I-HA by 190hHARE Flp-In 293 
cell lines (Figure 10). Surprisingly, although mAb-159 had no 
effect on HA uptake (even at 30 μg/ml), partial inhibition of 
specific HA endocytosis was observed with both mAb-30 and 
mAb-154 (Figure 10A). Negative controls for these effects in-
cluded the other four anti-HARE mAbs (#28, #174, #235, and 
#467), as well as IgG and mouse serum (not shown), any of 
which caused ≤8% inhibition at concentrations up to 30 μg/
ml. Experiments to assess the effects of various mAb combina-
tions on HA uptake at 37 °C showed that the inhibitory mAbs 
(#30 and #154) were not additive (Figure 10B). The maximum 
partial inhibition of specific HA endocytosis by mAb-30 or 
mAb-154 was, respectively, ~20–30% and 50–60%. 
Discussion
HA and CS turn over continuously in ECMs throughout the 
body. For humans, the HA turnover rate is so fast (e.g. ~24 h in 
skin) that about one-third of total body HA is degraded and re-
synthesized daily (6). Partially digested native HA molecules 
are released from tissue matrices as large HA fragments of ~106 
Da that would still contain bound aggregating proteoglycans 
(e.g. aggrecan or brevican) and Link proteins (31–33). The re-
leased ECM fragments would also contain covalently attached 
CS and other GAG chains, as well as a variety of bound ECM 
proteins and growth factors. Thus, multiple components asso-
ciated with these HA-proteoglycan fragments are simultane-
ously released from an ECM and then enter lymphatic vessels 
and flow to regional lymph nodes. Lymph nodes are the initial 
and primary sites for the clearance of the HA and CS, account-
ing for ~85% of the HA degradation. Liver is the second clear-
ance site, after the lymph node effluent enters the circulation, 
accounting for ~15% of the total body HA, and presumably CS, 
turnover. The clearance and degradation of HA and CS in liver 
and lymph nodes is mediated by HARE, which is expressed in 
the sinusoidal endothelial cells of these tissues (8–13). 
Although no studies have yet addressed its role in normal 
health and in various diseases or pathologies, HARE is likely 
to be important in human physiology. Despite the high turn-
over rate of HA, the normal steady-state concentration of HA 
in blood (i.e. 10–100 ng/ml) is very low (2, 6). The HA/CS 
clearance systems utilizing HARE in lymph node and liver, 
therefore, function very efficiently, indicating that the removal 
of HA from lymph fluid and blood is important for normal 
health. First, one would predict that, if HA levels increased, 
particularly if the HA mass was large, then the increased vis-
cosity of blood might create potentially adverse situations, e.g. 
erythrocyte passage in narrow microcapillaries could be im-
paired. Second, because HA binds to human fibrinogen (34) 
and stimulates fibrin clot formation in vitro (35), elevated HA 
levels could alter normal coagulation homeostasis. Finally, 
Figure 5. Kinetic and Scatchard analyses of 125I-HA binding to Flp-
In 293 cells expressing recombinant 190-kDa hHARE. 190hHARE cell 
lines #9 (■) and #14 (●) were cultured in 4- or 6-well plates until con-
fluent. The cells were incubated for 60 min at 37 °C in medium with-
out serum and then chilled to 4 °C for all subsequent steps. The cells 
were washed with HBSS, permeabilized with 0.055% digitonin for 15 
min, and then washed with HBSS. At the end of each experiment, cells 
were washed with HBSS and cell-associated radioactivity and cell pro-
tein were determined as described under “Experimental Procedures.” 
A, after washing the cells, medium containing 0.1 μg/ml 125I-HA with 
the indicated amount of unlabeled HA was added to each well, and 
the cells were allowed to bind the HA on ice for 90 min. Specific bind-
ing was ~90%, as assessed in the presence of the highest HA concen-
tration. B, the data in A for clones #9 and #14 were recalculated as spe-
cific HA binding (femtomoles of HA/106 cells). The data are the mean 
± S.D. of duplicates for each of the two clones (n = 4). C, after the cells 
were allowed to bind HA on ice for 90 min as in A, the medium was 
removed to determine free 125I-HA, and the cells were washed and 
cell-associated 125I-HA was determined. The specifically bound HA 
was calculated for the experiment shown in B, and the results are pre-
sented in the format of Scatchard (29) as the average of duplicates for 
each cell line. 
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several diseases, including some cancers (36), psoriasis (37), 
scleroderma (38), rheumatoid arthritis (39), and liver cirrhosis 
(40, 41), are associated with elevated levels of HA in serum. 
Over the last decade, numerous studies have suggested that 
the HA clearance function of liver can be used as a diagnostic 
tool to detect and monitor liver failure (42). This hepatic func-
tion of LECs may also be a prognostic indicator of success in 
liver transplant patients. 
In this study, we created an artificial cDNA to express a re-
combinant form of the small spleen hHARE isoform in stable 
cell lines. This enabled us to characterize for the first time the 
GAG specificity and endocytic activity of the small hHARE 
isoform in the absence of the larger hHARE isoform. Several 
key characteristics of the 190-kDa hHARE are very similar to 
those of the 175-kDa rHARE. Both smaller HARE isoforms are 
functional endocytic HA receptors with the appropriate, as 
yet unidentified, sorting signals for targeting HARE to coated 
pits and then through an intracellular receptor recycling itin-
erary. Each HARE, although expressed in different cell types, 
mediated the continuous endocytosis of HA and its delivery 
to lysosomes for degradation. The rate of hHARE recycling 
in Flp-In 293 cell lines (i.e. one cell surface equivalent per 7–9 
min) was comparable to that determined in primary rat LECs 
(17). The apparently slower rate of rHARE recycling in SK-
Hep-1 cell lines (~20 min) is likely due to a decreased capac-
ity of the coated pit pathway in this latter cell line (9, 43, 44), 
rather than to intrinsic differences between the recombinant 
rHARE and hHARE. The affinities of the smaller rHARE and 
hHARE were also very similar, with Kd values of 4.1 and 7.2 
nm, respectively. 
Two significant differences, which might be related, be-
tween the rat and human HARE proteins are their slightly 
Figure 6. Only some non-HA GAGs compete for 125I-HA endocytosis at 37 °C by stable cell lines expressing the recombinant 190-kDa hHARE. Cells 
from 190-kDa hHARE Flp-In 293 clones #9 and #14 were incubated at 37 °C for 3 h in medium containing 1.5 μg/ml 125I-HA with 3 to 100 μg/ml of 
the indicated GAG. The values for competition of 125I-HA internalization by unlabeled GAGs or HA (expressed as a percentage of the no-competi-
tor control) are the average of duplicates from the two clones (n = 4). A, keratan sulfate (▲), dermatan sulfate (♦), chondroitin (■), chondroitin sul-
fate A (▼), HA (●). B, heparan sulfate (◊), heparin (), chondroitin sulfate E (∆), chondroitin sulfate D (○), chondroitin C (□), and HA (●). 
Figure 7. Chondroitin sulfates and other GAGs do not compete well 
for 125I-HA binding at 4 °C by Flp-In 293 cells expressing the 190-kDa 
hHARE. After a serum-free incubation and wash with HBSS, cells 
from 190-kDa hHARE clones #9 and #14 were incubated at 4 °C for 2 
h in medium containing 1.5 μg/ml 125I-HA and 50 μg/ml of the indi-
cated GAG. The values for each GAG are the mean of duplicate sam-
ples from both clones (n = 4) ± S.E. 
Figure 8. Other GAGs compete for 125I-HA binding to recombi-
nant 190-kDa hHARE in a ligand blot assay. Extracts prepared from 
190hHARE clone #14 cells were subjected to SDS-PAGE and elec-
troblotted as described under “Experimental Procedures.” The nitro-
cellulose was blocked with TBS and 0.1% Tween 20 at room temper-
ature for 3 h, and 3-mm strips were cut and placed in Buffer 1 with 
0.5% sodium azide, 5 mm EDTA, 0.05 μg/ml 125I-HA, and 50 μg/ml 
of the indicated GAG or HA. The strips were incubated at 4 °C for 
2 h on a rocking platform. The medium was then removed, and the 
strips were washed extensively with TBST for 20 min, allowed to air 
dry, and attached to filter paper for autoradiography with BioMax MS 
film. The exposure shown was for 19.5 h at –85 °C with two intensify-
ing screens. The graph shows the average densitometry values ± S.E. 
from three separate samples for each GAG. 
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different GAG specificities and their very different profiles 
for anti-HARE mAb inhibition of HA binding. The 190-kDa 
hHARE has a broad specificity for sulfated and nonsulfated 
GAGs, yet this recognition is not indiscriminant, because HA 
binding is not affected by KS, HS, or Hep. Thus, the 190-kDa 
hHARE recognizes HA and chondroitin, the two least nega-
tively charged GAGs, as well as three CS variants with differ-
ent levels and patterns of sulfation. The two GAGs with the 
greatest negative charge, HS and Hep, are not recognized. In 
contrast, all the CS variants tested were able to compete for 
HA binding. Although the pattern of inhibition by CS variants 
was similar to that for the 175-kDa rHARE, it was not identi-
cal. In particular, the two HARE species differ quantitatively 
in their recognition of CS-C and CS-E. 
The GlcUA-GlcNAc disaccharide units in HA and the Gl-
cUA-GalNAc disaccharide units of chondroitin were recog-
nized by the 190-kDa hHARE. HARE also recognized all of 
the sulfated CS types tested, despite differences in the posi-
tion and number of sulfates among their disaccharide units. 
Chondroitins sulfated at GalNAc positions C4, C6, or C4,6 (i.e. 
CS-A, CS-C, and CS-E) or at C6 of GalNAc and C2 of GlcUA 
(i.e. CS-D) were effective competitors of HA binding, although 
none were as effective as HA. CS-A was a slightly better com-
petitor than the other CS types, all of which were essentially 
identical. DS (also called CS-B) was the weakest competitor. 
KS contains Gal rather than a uronic acid and was not a com-
petitor. Although Hep and HS are very highly sulfated GAGs, 
they were not able to compete for HA binding to the 190-kDa 
hHARE. Perhaps HARE can recognize N-acetyl groups in the 
amino sugars of some GAGs, but not the N-sulfated glucos-
amine residues characteristic of Hep and HS. 
The greatest difference in GAG specificity between the rat 
and human proteins was with Chon, which poorly competes 
for HA binding by the rHARE. The 190-kDa hHARE protein 
appears to recognize Chon almost as well as most of the CS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
types. These slight differences between species in relative pref-
erence for various GAGs may be reflected in the more dra-
matic differences in the inhibition of their HA binding abil-
ity by mAbs. HA binding and endocytosis by the small (or 
large) rat HARE proteins is completely blocked by mAb-174 
and partially blocked by mAb-235, whereas no inhibition of li-
gand binding or uptake was observed with the other five anti-
HARE mAbs that recognize these proteins in Western blots 
and various immunoprocedures. In contrast, we found here 
that mAb-30 and mAb-154 partially inhibit HA binding and 
endocytosis by the 190-kDa hHARE. The other anti-HARE 
mAbs, including mAb-174 and mAb-235, were not inhibitory. 
Thus, although mAb-30 and mAb-154 bind to both rHARE 
and hHARE, this binding only inhibits HA recognition by the 
latter protein. 
Another distinctive and unusual feature of the 190-kDa 
hHARE was that GAG inhibition of its binding to HA was 
temperature-sensitive. Although multiple GAGs were able 
to block the binding and endocytosis of 125I-HA mediated by 
Figure 9. The human and rat small HARE isoforms show different 
GAG specificities for competition of 125I-HA endocytosis. Flp-In 293 
190hHARE clones #9 and #14 (white bars), SK-HARE clones #26 and 
#35 (expressing recombinant the rat 175-kDa HARE), and liver sinu-
soidal endothelial cells (from freshly perfused rat liver) were incu-
bated at 37 °C for 3 h with medium containing either 1 μg/ml 125I-
HA and 30 μg/ml of the indicated GAG (for SK-HARE and liver 
cells) or 1.5 μg/ml 125I-HA and 100 μg/ml of the indicated GAG (for 
190hHARE 293 cells). Cells were then washed and lysed, and the ra-
dioactivity and protein content were determined as described un-
der “Experimental Procedures.” Each GAG value is the mean ± S.E. 
of at least four individual wells (e.g. two wells for each of two clones 
or LEC preparations) and is calculated as a percentage of the 125I-HA 
control (without competitor). 
Figure 10. Inhibition by anti-HARE mAbs of 125I-HA uptake by cells 
expressing recombinant 190-kDa hHARE. Flp-In 293 190hHARE 
clones #9 and #14 were cultured and processed as described in Fig-
ure 4. A, the cells were allowed to bind and endocytose 1.5 μg/ml of 
125I-HA for 3 h at 37 °C with no additions, or the noted concentration 
of anti-rat HARE mAbs 28 (●), 30 (■), 154(▲), 159 (▼), 174 (♦), 235 
(○), and 467 (□). The cells were processed as described under “Exper-
imental Procedures.” The values shown are the average of two repli-
cate wells from each clone (n = 4), expressed as a percentage of the no-
addition control specific binding values. Mouse IgG (not shown) at 10 
μg/ml was 103 ± 5% of the control value. Specific binding (CPM/μg 
of cell protein), as assessed in the presence of a 100-fold excess of un-
labeled HA, was 87%. B, the indicated purified antibodies were used 
singly or in combination, at concentrations of 20 μg/ml, in an exper-
iment performed as described in A. Nonspecific endocytosis was as-
sessed in the presence of 75 μg/ml unlabeled HA. 
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hHARE at 37 °C, none of these GAGs could compete for 125I-
HA binding at 4 °C. Presumably, the extracellular domain of 
the 190-kDa hHARE undergoes a substantial conformational 
change between 37 °C and 4 °C that virtually eliminates the 
binding of GAGs other than HA. However, because our bind-
ing studies were indirect and only monitored the binding of 
125I-HA, it is possible that a conformational change could also 
create a situation wherein both GAGs might bind to separate 
sites without interference. Distinguishing between these possi-
bilities must await further direct binding studies between the 
various GAGs and the purified 190-kDa hHARE or its extra-
cellular domain. 
Taken together the above results indicate that amino acid 
sequence differences between the small rat and human HARE 
proteins may alter their GAG specificity slightly. These se-
quence differences may also alter conformations that occur 
when mAbs bind to the proteins, so that GAG binding is af-
fected indirectly, and in a species dependent way, by forma-
tion of a mAb·HARE complex. It is likely that mAb-30 and 
mAb-154 recognize epitopes that are not directly involved in 
HA binding by hHARE but that steric factors limit interactions 
of the protein with HA. The finding that inhibition with either 
mAb is only partial indicates that hHARE likely contains mul-
tiple HA binding regions. It also indicates that each hHARE 
protein may bind more than one HA molecule. Again, these 
or other possible explanations will require epitope mapping 
studies and studies to define the GAG binding regions within 
the extracellular domain of HARE. 
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